MG132 treatment improves cellular HGPS phenotypes in vitro, and injection of the drug in the skeletal muscle of a mouse model of progeria (LmnaG609G/G609G) locally reduced SRSF-1 expression and progerin levels [14]. This evidence concerns the gene LMNA and progeroid syndrome.